[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612613":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":37,"locations":43,"responsibleParty":67,"collaborators":24,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":24,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Tan Tock Seng Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Amsler Grid","ACTIVE_COMPARATOR","The Amsler grid is a tool used to monitor the macula, the central part of the retina, for changes in vision that can be indicative of various eye conditions, particularly age-related macular degeneration (AMD). It helps detect and monitor metamorphopsia (distorted vision) or scotoma (blind spots) in the central visual field.",[13],"Diagnostic Test: Amsler Grid",{"label":15,"type":16,"description":17,"interventionNames":18},"AVIGA Arm","EXPERIMENTAL","The AVIGA system tracks eye movements following generated patterns projected on the screen. Assessment of affected and unaffected eyes can be achieved at home using any computer screen.\n\nAVIGA is a home-based gaze-tracking system for monitoring of high-risk eyes with wet-AMD.",[19],"Device: AVIGA",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST",[9],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":24},"DEVICE","AVIGA","The AVIGA system tracks these eye movements with generated patterns on the screen, a visual assessment of affected and unaffected eyes is achieved at home on any tablet or laptop computer.\n\nAVIGA is a home-based gaze-tracking system for hyperacuity monitoring of high-risk eyes with diagnosed wet-AMD.",[15],[31,34],{"name":32,"affiliation":5,"role":33},"Augustinus Laude, MBChB, MSc, FRCSEd (Ophth), FA","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":5,"role":36},"Zheng Kuang Noel Soh, BSc","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":24,"email":42},"Zheng Kuang, Noel Soh, BSc","CONTACT","+65 6357 3693","zheng.Kuang.soh@nhghealth.com.sg",[44],{"facility":5,"status":45,"city":46,"state":24,"zip":47,"country":46,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Singapore","308433","SG",{"type":50,"coordinates":51},"Point",[52,53],103.85007,1.28967,{"lat":53,"lon":52},[56,57,59,62,64,65],{"name":35,"role":40,"phone":41,"phoneExt":24,"email":42},{"name":58,"role":33,"phone":24,"phoneExt":24,"email":24},"Augustinus Laude, MBChB",{"name":60,"role":61,"phone":24,"phoneExt":24,"email":24},"Tock Han Lim, MBBS, FRCSEd, MMed (Ophth)","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":24,"phoneExt":24,"email":24},"Elizabeth May Tan Chin, Doctor of Medicine",{"name":35,"role":61,"phone":24,"phoneExt":24,"email":24},{"name":66,"role":61,"phone":24,"phoneExt":24,"email":24},"Ian Kai Wen Yeo, BSc",{"type":33,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Laude Augustinus","Senior Consultant","100612613","aviga3-cohort-20-100612613",false,"NCT07255859","AVIGA3 (Cohort 2.0)","AVIGA3: Using an 'Automated Vision Assessment and Impairment Detection Through Gaze Analysis' Through a Longitudinal, Open-labelled, Randomized Clinical Trial to Monitor Recurrence of Aged-related Macular Degeneration in a Home-based Setting (Cohort 2.0).","AVIGA3","Inclusion criteria\n\n1. Subjects in the age group ≥ 50 to 99 years old.\n2. Both genders\n3. Able to understand verbal spoken instructions in British\u002FAmerican English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation.\n4. Able to turn on and connect the web-camera to a computer independently or with the help of family.\n5. Subjects undergoing treatment for Wet-AMD without any signs and symptoms of recurrence of active AMD (AMD recurrence: choroidal neovascularisation, intraretinal or subretinal fluid is present) with OCT lesion fluid volume more than 2 mm3 or ILM height more than 250µm.\n6. Ability to comply with the study protocol, in the investigator's judgment.\n7. Subjects must be able to understand and provide informed consent. A signed informed consent form must be provided before any study assessments.\n\nExclusion criteria\n\n1. Unable to understand verbal spoken instructions and demonstrate device functionality and implementation.\n2. Unable to turn on and connect the web-camera to a computer independently.\n3. Any ocular surgery in the previous 3 months, or vitrectomy in the previous 12 months\n4. Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye\n5. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study\n6. Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye.\n7. History of idiopathic or autoimmune-associated uveitis in either eye\n8. Active ocular inflammation or suspected or active ocular or periocular infection in either eye.","ALL","50 Years","99 Years",{"count":82,"type":83},60,"ESTIMATED","INTERVENTIONAL",[86],"NA","Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.",[89],"Maculopathy",[91,92,93,94,95,96],"aged-related macular degeneration","choroidal neovascularization","wet aged-related macular degeneration","gaze tracking","dry aged-related macular degeneration","maculopathy","2026-06-21",{"date":99,"type":100},"2026-06-24","ACTUAL",{"date":102,"type":100},"2025-06-16",{"date":104,"type":83},"2027-12-31",{"name":5,"class":6},1]